1. Reproducible human efficacy
The strongest signal will be controlled human data showing a clinically meaningful increase in durable terminal hairs. Laboratory induction and temporary thickening address different endpoints.
2. Persistence across cycles
A result that fades within months has a different commercial profile from a follicle that continues normal cycling. Follow-up duration will shape both clinical value and pricing.
3. Manufacturing consistency
A procedure must work beyond one specialist laboratory. Standardised expansion, quality controls and transport are prerequisites for scaling through clinic networks.
4. Regulatory development
Formal trial progression and transparent interaction with major regulators matter more than proposed launch dates. Relevant evidence includes completed early studies, published results and pivotal trial design.
5. Delivery economics
Even effective cells must be placed efficiently and with natural orientation. Automation, clinic training and cost per treated area will determine whether the result remains a limited specialist procedure or becomes more broadly accessible.